Robert Mutter is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 205 publications with 2,944 citations (h-index 29); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 19 Aug 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- ADAR1 promotes Okazaki fragment maturation and is a target for breast cancer therapy
Mayo Clinic Rochester
FY2026$589,841R01CA299196 - ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer
Mayo Clinic Rochester
FY2026$369,203R01CA272602 - ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer
Mayo Clinic Rochester
FY2025$369,203R01CA272602
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
New England Journal of Medicine
2025 - Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation
International Journal of Radiation Oncology*Biology*Physics
2024 - Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy
Drug Resistance Updates
2024 - Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report
International Journal of Particle Therapy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”